Cidara Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Cidara Therapeutics focuses on CD388 development after divesting rezafungin, reporting a net loss of $169.8 million for fiscal year 2024.
Cidara Therapeutics has filed its annual 10-K report, highlighting the commercial launch of REZZAYO, advancements in its Cloudbreak platform, and ongoing clinical trials.